WO2012051601A3 - Heteroarylthio compounds - Google Patents
Heteroarylthio compounds Download PDFInfo
- Publication number
- WO2012051601A3 WO2012051601A3 PCT/US2011/056479 US2011056479W WO2012051601A3 WO 2012051601 A3 WO2012051601 A3 WO 2012051601A3 US 2011056479 W US2011056479 W US 2011056479W WO 2012051601 A3 WO2012051601 A3 WO 2012051601A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heteroarylthio
- compounds
- treatment
- covalently linked
- neurological conditions
- Prior art date
Links
- 125000005368 heteroarylthio group Chemical group 0.000 title abstract 2
- 230000000926 neurological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/42—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Heteroarylthio compounds covalently linked to an arylpiperazine moiety for the treatment of neurological conditions.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/879,142 US20130289047A1 (en) | 2010-10-14 | 2011-10-14 | Heteroarylthio derivatives and analogues |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39334910P | 2010-10-14 | 2010-10-14 | |
US61/393,349 | 2010-10-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012051601A2 WO2012051601A2 (en) | 2012-04-19 |
WO2012051601A3 true WO2012051601A3 (en) | 2012-06-21 |
Family
ID=45939022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/056479 WO2012051601A2 (en) | 2010-10-14 | 2011-10-14 | Heteroarylthio compounds |
Country Status (2)
Country | Link |
---|---|
US (1) | US20130289047A1 (en) |
WO (1) | WO2012051601A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103626748B (en) * | 2013-12-10 | 2016-08-17 | 浙江工业大学 | A kind of diazoles compound containing pyridine and preparation and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0977765A (en) * | 1995-09-18 | 1997-03-25 | Roussel Morishita Kk | 2-((1h-benzimidazol-2-yl)thiomethyl)-4-substituted amino-5-pyrimidinecarboxylic acid ester derivative |
US20070066542A1 (en) * | 2003-05-27 | 2007-03-22 | Societe De Conseils De Recherches Et D'application Scientifiques (S.C.R.A.S.) | Novel imidazole derivatives, their preparation and their use as medicaments |
US20090069340A1 (en) * | 2004-12-27 | 2009-03-12 | Astrazeneca Ab | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4425146A1 (en) * | 1994-07-15 | 1996-01-18 | Basf Ag | Use of heterocyclic compounds |
-
2011
- 2011-10-14 US US13/879,142 patent/US20130289047A1/en not_active Abandoned
- 2011-10-14 WO PCT/US2011/056479 patent/WO2012051601A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0977765A (en) * | 1995-09-18 | 1997-03-25 | Roussel Morishita Kk | 2-((1h-benzimidazol-2-yl)thiomethyl)-4-substituted amino-5-pyrimidinecarboxylic acid ester derivative |
US20070066542A1 (en) * | 2003-05-27 | 2007-03-22 | Societe De Conseils De Recherches Et D'application Scientifiques (S.C.R.A.S.) | Novel imidazole derivatives, their preparation and their use as medicaments |
US20090069340A1 (en) * | 2004-12-27 | 2009-03-12 | Astrazeneca Ab | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders |
Also Published As
Publication number | Publication date |
---|---|
WO2012051601A2 (en) | 2012-04-19 |
US20130289047A1 (en) | 2013-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20130357T1 (en) | Novel compounds useful for the treatment of degenerative and inflammatory diseases. | |
PL2630108T3 (en) | Process for the preparation of 2,3,3,3 tetrafluoropropene | |
WO2011140517A9 (en) | Methods for treating diseases of the lung | |
IL230635A (en) | 1,2,3,4-tetrahydroquinoline derivative useful for the treatment of diabetes | |
WO2012061607A3 (en) | Compositions comprising functionalized carbon-based nanostructures and related methods | |
WO2011159945A9 (en) | Methods for treating neurological conditions | |
WO2011069063A3 (en) | Multicyclic compounds and methods of use thereof | |
AU2012213775A8 (en) | 7-azaindole derivatives | |
WO2012025944A3 (en) | Sitagliptin, salts and polymorphs thereof | |
WO2010150211A3 (en) | Use of derivatives of indoles for the treatment of cancer | |
WO2011088027A8 (en) | Compounds and methods | |
WO2012071414A3 (en) | Quinoxaline compounds and uses thereof | |
WO2011047091A9 (en) | Methods for treating traumatic brain injury | |
WO2012104823A3 (en) | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases | |
WO2014086453A8 (en) | Azaheterobicyclic compounds | |
IL220846A0 (en) | Process for the preparation of nebivolol | |
IL226153A (en) | Process for the preparation of nebivolol | |
WO2012064743A3 (en) | Methods for improving heart function | |
EP3081097B8 (en) | Composition for the treatment of infertility | |
WO2012054782A3 (en) | Fluoroalkoxylation of organic compounds | |
WO2012068332A9 (en) | Methods for treating early stage or mild neurological disorders | |
WO2011000945A3 (en) | Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns | |
WO2012051601A3 (en) | Heteroarylthio compounds | |
EA201390620A1 (en) | OXAZOLO [5,4-b] PIRIDIN-5-ILY COMPOUNDS | |
WO2012051251A8 (en) | Methods of treating giardiasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11833536 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13879142 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11833536 Country of ref document: EP Kind code of ref document: A2 |